New heart failure drug enters early human testing

NCT ID NCT07465653

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This early-stage trial is testing an experimental drug called HJB647 in 12 adults with stable chronic heart failure and reduced pumping ability. The study aims to check the drug's safety and how the body processes it at two different doses. Participants will receive both the drug and a placebo at different times to compare effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HJB647 (an experimental drug in capsule form)
What this could lead to: If successful, this could point toward a new treatment option for chronic heart failure with reduced ejection fraction.
What could go wrong: This is a very early Phase 1 trial with only 12 participants, so it is primarily testing safety, not effectiveness. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH REDUCED EJECTION FRACTION

Contacts and locations

Locations

Jacksonville Center for Clinical
RECRUITING

Jacksonville, Florida, 32216, United States
Nature Coast Clinical Research LLC
RECRUITING

Inverness, Florida, 34452, United States
Novartis Investigative Site
RECRUITING

Montreal, Quebec, H1T 1C8, Canada
Synergy Healthcare
RECRUITING

Bradenton, Florida, 34208, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.